US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
INVO BioScience Inc (INVO)
INVO BioScience Inc (INVO) ニュース

INVO

INVO BioScience (INVO)

INVO BioScience Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:INVO

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/22	05 : 39	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:INVO	INVO BioScience Inc
2024/05/16	05 : 51	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2024/05/16	05 : 15	GlobeNewswire Inc.	INVO Reports Record First Quarter 2024 Financial Results	NASDAQ:INVO	INVO BioScience Inc
2024/05/07	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2024/04/17	23 : 25	AllPennyStocks.com	Micro Cap Massively Bid Up Before Opening Bell	NASDAQ:INVO	INVO BioScience Inc
2024/04/17	05 : 59	GlobeNewswire Inc.	INVO Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:INVO	INVO BioScience Inc
2024/02/07	00 : 24	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:INVO	INVO BioScience Inc
2024/02/01	23 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2024/01/23	22 : 00	GlobeNewswire Inc.	NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)	NASDAQ:INVO	INVO BioScience Inc
2024/01/17	22 : 00	GlobeNewswire Inc.	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors	NASDAQ:INVO	INVO BioScience Inc
2024/01/17	07 : 29	Edgar (US Regulatory)	Form S-4 - Registration of securities, business combinations	NASDAQ:INVO	INVO BioScience Inc
2024/01/11	06 : 46	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:INVO	INVO BioScience Inc
2024/01/11	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2024/01/04	07 : 29	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2023/12/29	07 : 04	Edgar (US Regulatory)	Form 424B7 - Prospectus [Rule 424(b)(7)]	NASDAQ:INVO	INVO BioScience Inc
2023/12/29	07 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2023/12/14	07 : 08	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:INVO	INVO BioScience Inc
2023/12/14	06 : 53	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2023/12/11	22 : 00	PR Newswire (US)	NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal	NASDAQ:INVO	INVO BioScience Inc
2023/11/29	07 : 18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2023/11/28	23 : 00	PR Newswire (US)	INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement	NASDAQ:INVO	INVO BioScience Inc
2023/11/25	03 : 08	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:INVO	INVO BioScience Inc
2023/11/21	06 : 59	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2023/11/14	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2023/11/14	06 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:INVO	INVO BioScience Inc
2023/11/14	06 : 01	PR Newswire (US)	INVO Reports Record Third Quarter 2023 Financial Results	NASDAQ:INVO	INVO BioScience Inc
2023/11/13	23 : 23	Edgar (US Regulatory)	Form SC TO-C - Written communication relating to an issuer or third party	NASDAQ:INVO	INVO BioScience Inc
2023/11/13	23 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INVO	INVO BioScience Inc
2023/11/13	23 : 12	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:INVO	INVO BioScience Inc
2023/11/10	23 : 00	PR Newswire (US)	NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger	NASDAQ:INVO	INVO BioScience Inc

Showing the most relevant articles for your search:NASDAQ:INVO

1 2 3 4 5 6 7 8 次へ >>

Gold vs US Dollar

American Express

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約